Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242605 | 0.71 | PARP1 (0.43) | CYP2C9CYP2C19L3MBTL1STSALDH1A1 | |
| SCHEMBL5171096 | 0.71 | MEN1 (0.41) | KMT2ACYP2C9CYP2C19L3MBTL1NPSR1 | |
| SCHEMBL4123910 | 0.69 | FKBP1A (0.40) | CYP2C9CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL31266306 | 0.69 | KMT2A (0.41) | KMT2AL3MBTL1SIGMAR1 | |
| SCHEMBL3236730 | 0.68 | CYP1A2 (0.37) | KMT2ACYP2C9CYP2C19L3MBTL1NPSR1 | |
| SCHEMBL5252554 | 0.67 | HTT (0.44) | KMT2ACYP2C9CYP2C19SLC6A4POLB | |
| SCHEMBL31266021 | 0.67 | KMT2A (0.39) | KMT2ACYP2C9CYP2C19SLC6A4SLC6A3 | |
| SCHEMBL31266232 | 0.65 | KMT2A (0.38) | KMT2ACYP2C9CYP2C19SLC6A4SLC6A3 | |
| SCHEMBL27358578 | 0.65 | ALDH1A1 (0.52) | KMT2APOLBL3MBTL1ALDH1A1 | |
| SCHEMBL3339309 | 0.65 | CYP1A2 (0.37) | KMT2ACYP2C9CYP2C19L3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| CN-101360720-A | Novel 2-aminopyrimidinone derivatives and their use | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1951680-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | KMT2A 2006/4885CYP2C9 1988/4885CYP2C19 529/4885 |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | KMT2A 2006/4885CYP2C9 1988/4885CYP2C19 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.